Antidote Health
Shelly Hod Moyal has a strong background in venture capital and investment. In 2013, they co-founded iAngels, a women-led venture capital firm and investment platform. As a Founding Partner and Co-CEO of iAngels, they offer accredited investors worldwide access to tech startups and scaleup investment opportunities from Israel. Shelly is also a General Partner in the iNgenuity Fund, an institutional fund backed by the European Investment Fund.
Shelly has also held various board positions in different companies. In 2022, they became a Board Director at Seed-X, Vyzer, and Guardz. Shelly has been a Board Observer at H2Pro, Ltd. since 2019. In addition, Shelly serves as a Board Director for binah.ai, Innovopro, Antidote Health, Urecsys, and Medorion.
Their expertise and experience in the field make their a valuable asset in guiding and advising these companies in their strategic decision-making processes.
Shelly Hod Moyal completed their Master of Business Administration (MBA) at Northwestern University - Kellogg School of Management from 2013 to 2015. Prior to that, they earned a Bachelor's degree in Economics from Hunter College, where they studied from 2005 to 2007.
This person is not in any teams
This person is not in any offices
Antidote Health
Antidote Health was founded by a core team of medical healthcare professionals and Israeli cyber experts driven by the belief that everyday healthcare is a fundamental right and should be accessible to all. Seeing the pain in American society where so many people lack satisfactory healthcare, they decided to develop a telehealth platform that would make it possible to provide premium healthcare that anyone can afford.